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Abstract 
Introduction: In Ethiopia human immunodeficiency virus adult prevalence is estimated 
to be 1.14% in 2014. In the same year there were an estimated 0.8 million people living 
with HIV and there were also approximately 35,600 AIDS related deaths in the country. 
There are more than 300,000 people who are on ART among which 1.5% are on 
second line in the country. Body weight of HIV patients has been an important 
diagnostic and evaluation measure. It is recognized as one of the first criteria for the 
clinical definition of acquired immuno deficiency syndrome. It is also an important 
predictors of treatment outcome, dropout rate from HIV care, and risk of death. But 
there is lack of information how it is changing over time and the predictors affecting it in 
HIV patients already on ART. 
Objective: The objective of this study was to assess the trend of BMI over time and 
factors affecting it among HIV patients on second line ART in Amhara region.                                                                                         
Methods: Institution based retrospective follow up study was conducted among adults 
on second line ART in referral hospitals Amhara region. Total 1016 patients were 
included in the study. Data were collected from patient charts and entered to EPI info 
version 7 and was analyzed using STATA version 14.0. Summary measures were done 
for baseline characteristics. Exploratory data analysis for the body mass index of 
patients including individual profile plot, mean profile plot was done. Predictors with p 
value < 0.25 in bivariable analysis were entered to the final linear mixed model. 
 
Result From a total of 1016 participants 538 (52.95%) were males and median age of 
participants was 33 (IQR=14). Median follow up time was 17 months. The evolution of 
BMI showed variation between individuals and within individuals over time. The average 
change of BMI has showed  a positive linear increase over time. Significant predictors of 
BMI were treatment duration (𝛽=0.04 95% CI 0.01,  0.07), age (𝛽=0.04 95% CI 0.01, 
0.07), NGO employement (𝛽 =1.9 95% CI 0.24, 3.52) good adherence (𝛽=0.6 95% CI 
0.04    1.14) INH prophylaxis (𝛽 =0.7, 95% CI 0.22,  1.36), CPT (𝛽=0.8, 95% CI 0.25, 
1.39), ambulatory (𝛽=1.6, 95% CI -1.91   -1.26), bedridden (𝛽=1.8, 95% CI -2.45   -1.21), 
WHO stage III (𝛽 = -0.4 95% CI -0.62   -0.16), WHO stage IV (𝛽=-0.8 95% -1.17   -0.36) 
and CD4 count (𝛽 =0.001 95% CI 0.0007, 0.0014). Time interaction of tertiary education 
(𝛽=0.02, 0.003, 0.04), ambulatory (𝛽 =0.03 95% CI 0.013    0.05), WHO stage III (𝛽 =0.01 
95% CI 0.013    0.02).  
 
Conclusion and recommendations There was a linear increment of BMI over time in 
HIV patients on second line ART. Age, treatment duration, INH prophylaxis, CPT 
prophylaxis, Occupational status, CD4 count, ART adherence, Functional status, WHO 
stage were significant predictors of BMI.  Prophylaxis for opportunistic infection shall be 
given to all patients, good adherence, staying long on treatment shall be enhanced. 
KEY WORDS Amhara, BMI, HIV, Second line ART, Linear mixed effect model
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1. INTRODUCTION 
1.1 STATEMENT OF THE PROBLEM 
Human immunodeficiency virus/Acquired Immunodeficiency syndrome (HIV/AIDS) is 
one of the most destructive diseases human kind has ever faced. In 2015 there were 
2.1 million [1.8 million–2.4 million] new HIV infections worldwide, adding up to a total of 
36.7 million [34.0 million–39.8 million] people living with HIV. The disease is a leading 
cause of death worldwide. Since the beginning of the pandemic, more than three 
decades ago; approximately 30 million people have died of AIDS-related illnesses(1, 2).  
From the world total population of people living with HIV, 71% are found in sub-Saharan 
Africa. Ten countries including Ethiopia account for 81% of all people living with HIV in 
the region and the estimated AIDS related deaths were 1.1 million in 2013(3). 
In Ethiopia HIV adult prevalence is estimated to be 1.14% in 2014. In the same year 
there were an estimated 769,600 people living with HIV and there were also 
approximately 35,600 AIDS related deaths in the country(4). 
The introduction of anti retroviral therapy (ART) has resulted in a massive reduction in 
the mortality of HIV patients(5). In 2014 globally as many as 13,950,296 people were 
accessing ART(3). In 2013/14 in Ethiopia 308,860 to 344,344 people living with 
HIV/AIDS (PLWHA) were using ART. Among which 1.5% were on second-line 
treatment. The Amhara regional state in northwest Ethiopia comprises the highest 
proportion of ART users, with 102,088 individuals(6). 
Body weight of HIV patients has been an important diagnostic and evaluation measure. 
It is  recognised as one of the first criteria for the clinical definition of AIDS. The current 
World Health Organization (WHO) clinical staging of the disease also includes moderate 
unexplained weight loss (<10% presumed or measured body weight, stage 2), 
unexplained severe weight loss (>10% of body weight or BMI < 18.5 kg/m2, clinical 
stage 3) and HIV wasting syndrome (Unexplained severe wasting, stunting or severe 
malnutrition, clinical stage 4) as criteria to  define advanced HIV infection(7). 
Weight loss and wasting remain common problems and also the strongest independent 
predictors of mortality even in the era of highly active antiretroviral therapy (8, 9).  
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Increment in BMI of patients is generally associated with a better CD4+ T cell 
recovery(10). The risk of death from AIDS is also higher in patients who are 
underweight when compared to those who are normal and overweight/obese(11). In the 
era of effective ART being overweight and obese has also become another growing 
problem exposing HIV patients to several chronic illnesses in addition to the virus itself. 
(12) 
The BMI of HIV patients is affected by different factors including gender, age at ART 
initiation, baseline CD4 count, initial body weight, initial hemoglobin, (13) viral load, CD4 
count change(14) presence of Tuberculosis and other opportunistic infections, 
adherence to treatment and marital status(15) 
Even though there is a high early mortality in patients on second line ART (16) most of 
the literatures conducted on this key factor which determine mortality, are done in 
patients on first line ART and are also conducted in developed countries. This study will 
answer the research question that how the BMI of patients on the second line ART is 
changing and what factors are affecting it. The findings of this study will be a good input 
for all decision or policy makers at every stage of the health care system to reduce 
mortality due to the disease. 
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1.2 LITERATURE REVIEW 
1.2.1 Trend of Body Mass Index 
BMI of HIV patients is among the many important staging criteria and an important 
prognostic factor determining the outcome of the disease. Studies show that the 
mortality and morbidity of these patients is highly affected by the change in their BMI. 
Especially before the initiation of HAART weight loss and wasting have been major co-
morbidities. And this problem has continued even in the era of HAART (7-9). On the 
other hand there is also an emerging and fast growing problem related to ART that is 
excessive weight gain leading to a high occurrence of overweight and obesity in HIV 
patients.(12)  a study showed that for a one unit increase in BMI of HIV patients the risk 
of cardio-vascular events have increased by 18%-20%(17).  
Treatment outcome of patients was found to be significantly associated with their body 
weight change (18-21). A study conducted in sub-Saharan Africa showed weight loss of 
> 10% as an important predictor of dropout from care after ART is initiated (22).  
The risk of death for these patients is also associated with their body weight (16, 23-26).  
In a study conducted in South Africa the prevalence of overweight has increased by 
10% from 27% baseline to 37% after one year of antiretroviral therapy. Whereas 
underweight prevalence has decreased by 5% from the baseline.(27)  
HIV patients can get or loss weight depending on many factors. In a study conducted in 
Abidjan the prevalence of being overweight or obese increased significantly among 
women, from 30 % at baseline to 38 % after two years of follow up, but remained 
unchanged among men(28).  Another follow up study found the prevalence of wasting in 
patients on ART to be 14%. Significantly large proportion of this cohort (58%) continues 
to lose weight and 33% met one of the definitions of HIV-associated wasting (9).  
In a systematic review conducted on association between nutritional status and the 
immune response in HIV positive patients under HAART, weight loss is still prevalent 
among these patients in Low and Middle Income Countries and contribute to excess 
early mortality(29). 
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1.2.2 Factors affecting body mass index 
Studies have been conducted to determine factors affecting the weight change in HIV 
patients on ART. In a study conducted in resource limited settings from the Southern-, 
East-, West- and Central African regions and the Asia-Pacific region weight change in 
the first year after initiation of ART is higher in men than women, men loss weight when 
women stay the same, and after second year of therapy women are more likely to have 
weight gain as compared to men (13). A study conducted in Tanzania showed that 
women have decreased risk of significant weight loss after ART initiation when 
compared to men. The same study also showed that age to be significant predictor of 
weight change, with older patients having higher risk of long term weight loss(30). 
Another study conducted in Cameroon also showed that age group of less than 30 
years and married individuals had a good evolution(15). But a study in low resource 
setting found patients younger than 29 years old to have a higher risk of weight loss as 
compared to those with in the age group of 35 to 40 years(13).   
A study conducted in Hanoi, Vietnam showed moderate/high alcohol drinking, tobacco 
smoking, and poor adherence are significantly associated with negative weight 
change(31). 
In a study conducted in Tanzania as the hemoglobin level of patients increases the risk 
of significant weight loss has decreased.CD4 count increment of HIV patients is also 
inversely related with risk of weight loss (30). Baseline CD4 count < 200 was found to 
be significantly associated with negative change in weight, and CD4 Count greater than 
199 at baseline was significantly associated with lower risk of weight loss > 5% in 
studies conducted in Hanoi, Vietnam and resource limited settings respectively(13, 31). 
An increase in the viral load of patients is associated with a negative change in the body 
weight. Weight change also has a significant difference with respect to duration of 
treatment (14, 15, 31). But, in a study conducted in South Africa, neither ART duration & 
CD4 count nor viral load was independently associated with body weight change(32). 
Body weight change of patients is also determined by baseline WHO stage. The higher 
the WHO stage the higher risk of weight gain. Patients with lower baseline weight have 
also positive change in their weight than those with higher baseline weight (13). The 
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presence of Opportunistic infections was significantly associated with negative change 
(15).  Whereas presence of Tuberculosis had no effect on weight change(33). 
Treatment Related Factors 
Antiretroviral therapy regimen and duration of therapy are also significant predictors of 
the body weight change (13, 20, 34).   
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1.2.3 CONCEPTUAL FRAMEWORK  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1Conceptual Framework adopted from review of literatures (14, 16, 21, 32, 
34). 
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1.3 JUSTIFICATION OF THE STUDY 
Although the BMI of HIV infected patients is an important predictor of mortality and other 
treatment outcomes, there is lack of information on this important predictor especially in 
our country. Most of published studies conducted are on patients in developed 
countries. And even those few studies conducted in similar settings have used models 
that don’t show the change over time. Since this study is conducted using repeated 
measure (linear mixed effect model) which can show the changes over time, includes 
both time varying and non time varying predictors, and random effects, it will fill both the 
lack of information and methodological gaps. We believe the results of the study can 
help decision making, program evaluation and help to identify the possible intervention 
areas to decrease morbidity and death from the disease. 
The results of this study will also be a good input for future researches. 
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2. OBJECTIVES  
2.1 General Objective 
 
 To examine trend of BMI over time and factors affecting it among adult 
HIV infected patients on second line ART in Amhara region, from February 
2008 to February 2016 
2.2 Specific Objectives 
 
 To examine the trend of BMI over time among adult HIV infected patients 
on second line ART  
 
 To determine factors affecting BMI evolution among adult HIV infected 
patients on second line ART  
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3. METHODS AND MATERIALS 
3.1.0 Study design 
Institution based retrospective follow up study was conducted among adults on second 
line ART 
3.1.1 Study area and period 
This study was conducted in Amhara regional state which is one of the nine regions of 
Ethiopia. It has 17 Hospitals, 520 Health Centers and 2,941 Health Posts according to 
FMOH health and health related indicators report of 2010. There are 102 088 
individuals on ART in the region. Referal hospitals in which the study was conducted 
were Gondar university, FelegeHiwot, Debremarkos, Debrebirhan, Dessee, 
Finoteselam, Woldya and Debre Tabor Hospitals. These hospitals provide service for 
the largest proportion of patients on second line ART. 
3.1.2 Source population and study population 
 The source population of this study was all Adults above the age of 24 years who were       
. on second line ART in the Amhara region.  
 The study population was adult HIV infected patients on second line ART in the 
selected hospitals who started second line therapy between February 2008 and 
February 2016. 
3.1.3 Inclusion and exclusion criteria 
All adults above the age of 24 years who were on second line ART in the selected 
hospitals were included, however patients whose weight was measured only once, 
Patients for whom baseline height was not measured and patients who were pregnant 
were excluded from the study. 
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3.1.4 Sample size and sampling procedure 
We have selected referral hospitals in the region. 
The sample size for this study was done based on the following assumption 
All subjects measured at m = 10 time points  
We used 90% power to detect a difference, d of 0.75 kg/m2  
The sample size formula was taken from sample size for longitudinal studies(35). 
                                    
𝑛 =  
2𝜎2(1 + (𝑚 − 1)𝜌)(𝑍𝛼
2⁄
+ 𝑍1−𝛽)
𝑚𝑑2
 
 
The standard deviation for calculating the sample size in this study was taken from a 
study in Kano, Northwestern Nigeria(36).  
 
𝑛 =  
2𝑥62(1+(10−1)0.5)(1.96+1.64)
10(0.75)2
     = 912.38  ≈ 913 
 
• 𝛿 (standard deviation)= 6   
• 𝜌  = 0.5 Constant within-subject correlation  
• Where α = significant level (0.05)  
• 1-β = the power of the study = 90%  
• Z1-α/2 =Z-value attributed to α/2 (1.96)  
• Z1-β = Z-value attributed to 1-β (1.64)  
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Sampling Procedure 
We have found 1016 patients who fulfill the criteria and have included them in the study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Schematic presentation of the study participant selection 
 
*GUH=Gondar University Hospital        *D/TRH= Debretabor Hospital 
*FRH = Felegehiwot Referal Hospital    *FSH= Finoteselam Hospital 
*DRH = Dessie Referral Hospital            *DMH= Debremarkos Hospital 
*Debrebirhan= Debrebirhan Hospital   *Woldiya= Woldiya Hospital 
 
 
  
 
 
 
GUH = 78 FRH =313 DRH = 530 D/TRH = 26 
FSH = 33 
DMH =42 DBH=26 Woldiya = 
162 
TOTAL Patients who fulfill the inclusion criteria  
GUH = 48 FRH = 264 DRH = 498 D/TRH = 21 
FSH = 7 DMH = 19 Debrebirhan 
= 24 
Woldiya = 
135 
TOTAL patients included in the study = 1016 
TOTAL adult HIV patients on second line ART = 1210 
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3.1.5 Variables of the study  
Dependent variable:  Body Mass Index 
Independent variables 
Socio-demographic variables: Gender, Age, Educational Status, Occupational status 
Behavioral Factors:  Adherence 
Treatment Related factors: Duration of Treatment, Isoniazide prophylaxis (INH), 
Cotrimoxazole Prophylaxis therapy (CPT), ART Regimen. 
Clinical Factors: WHO Stage, Tuberculosis, Opportunistic Infections, CD4 count, 
Functional status 
3.1.6 Operational definition 
 Adherence to ART: Good adherence is when a patient arrives > 95% of his or her visits 
within 3 days or appointment date. Fair adherence is when a patient arrives 85% - 94% 
of his or her visits within 3 days or appointment date. Poor adherence is when a patient 
arrives < 85% of his or her visits within 3 days or appointment date.   
3.1.7 Data collection tool and Data collection procedures  
Data collection tool were prepared in English. Supervised by three health professionals 
with BSc. degree, twelve health care professionals (Nurses & Public Health Officers) 
have collected the data after they identified records which meet the inclusion and 
exclusion criteria. 
The quality of data was assured by giving training for data collectors, by close 
supervision and giving prompt feedback. The collected data was checked for 
inconsistencies, coding error, out of range, completeness, accuracy, clarity, missing 
values and appropriate corrections was made by the principal investigator and 
supervisors.  
3.1.8 Data processing and analysis 
The data was cleansed & entered in to EPI info version 7 and analyzed using STATA 
version 14.0. BMI of patients was computed by dividing their weight in kg by baseline 
hight in meters square. Exploratory data analysis for the weight of patients including 
individual profile plot, mean profile plot, descriptive and summary statistics were done. 
Normality assumption was checked by Q-Q plot. To determine the factors associated 
13 
 
with BMI of patients univariate analysis for each independent variable was assessed 
and those found to be significant (p-value<0.25) were selected for the multivariate 
analysis. The need for random intercept and random slope was checked by likelihood 
ratio test and finally linear mixed effect model was  fitted to evaluate the longitudinal 
change in the BMI of these patients over time and associations with covariates across 
all visits. The goodness of fit of the model was checked using a model diagnostic plot.  
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4.  Ethical consideration 
Ethical clearance was obtained from Institutional Review Board of Institute of Public 
Health, CMHS, and University of Gondar. Permission letter was obtained from the 
hospitals administration and the ART focal persons in all the hospitals. Names and 
unique ART numbers of patients was not included during data collection. 
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5. RESULTS 
We had a total of 1016 adult patients from which majority of them were taken from 
Dessie referal hospital 498 (49%). There were a maximum of 12 and a minimum of 2 
measurements of weight and other time varying predictor variables. Almost all visits 
were not balanced in their time of measurements.   
5.1 BASELINE SOCIO-DEMOGRAPHIC CHARACTERSTICS       
Among the total sample 538 (52.95%) were males. All participants were above or equal 
to the age of 24 with median age of 33 year (IQR of 14). The largest proportion of these 
patients 370 (37.11%) were unemployed and 371 (36.9%) have attended secondary 
school (Table 1).  
5.2 CLINICAL AND TREATMENT RELATED BASELINE CHARACTERSTICS 
At the initiation of second line ART majority of them 393 (45.54%) were at WHO stage I 
and 324 (37.54%) were at WHO stage III. Large proportion of participants 871 (86%) 
were working at base line the rest 114 (11.25%) and 28 (2.75%) were ambulatory and 
bed ridden respectively. The median CD4 count was 253 with IQR of 252. Regarding 
the opportunistic infection 661 (66.1%) of the participants had history of at least one 
opportunistic infection during the follow up time. And 194 (19.38%) patients had history 
of  Tuberculosis. The widely used second line regimen 442 (43.5%) at the initiation was 
TDF based regimen. INH and CPT was given for  247 (24.87%) and 256 (25.65%) of 
participants respectively (Table 2, Figure 1). 
 
Figure 3 Pie chart of Baseline WHO stage of HIV patients on second line ART in 
Amhara region 2008 - 2016 
1-stage1 2-stage2 
 3-stage3Stage III 4-stage4 
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Table 1 Baseline socio demographic characterstics of adult patients on second 
line ART in Amhara region, 2008 to 2016 
Variables Number Percentage  
Age  
                             25-34 547 53.89  
35-44 333 32.81        
45-54 104 10.25      
55-64 26 2.56      
>  65 5 0.49       
Name of Hospital    
Dessie Referal  498 49  
Felegehiwot  264 26  
Woldie 135 13.3  
Gondar University1  119 11.7  
Sex 
Female  478 47.05  
Male 538 52.95  
Educational status    
Illiterates 315 31  
Primary education 201 19.78  
Secondary education 371 31.20  
Tertiary education 118 11.61  
Occupation 
Unemployed  370 36.41  
Governmental 286 28.14  
Non-Governmental 21 2.06  
Private 66 6.49  
Other 254 25  
Gondar university1 :Gondar Universi,Finoteselam,Debremarkos,Debrebirhan,Debretabor 
Occupation Others : Daily labourer, students   
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Table 2 Clinial and treatment related baseline characterstics of adult patients on 
second line ART in Amhara region, 2008 to 2016 
Variables Frequency  Percentage  
WHO Stage 
  
                       Stage I 393 45.54 
                      Stage II 66 7.65 
                      Stage III 324 37.54 
                       Stage IV 80 9.27 
Functional status   
Working 871 86 
Ambulatory 114 11.25 
Bed ridden 28 2.75 
Opportunistic infection   
No 339 33.9 
Yes 661 66.1 
Tuberculosis   
No  807 8.62 
Yes 194 19.38 
CPT given   
No 742 74.36 
Yes 256 25.56 
INH given   
No  746 75.13 
Yes 247 24.87 
ART regimen    
ABC based regimen 319 41.4 
TDF based regimen 442 43.5 
AZT based regimen 197 19.39 
Others 58 5.71 
Others= entecavir, stavudine based regimens  
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5.3 BMI status of patients across different visits  
At base line 392 (38.5%) of all patients were under weight and 92 (9%) were over 
weight. As time goes on  the under weight status of patients decreases up to the nineth 
observation and increases to the twelveth observation but the prevalence of overweight 
increases through out the observations (Figure 4) 
 
 
 
 
 
Figure 4  BMI status of patients on second line ART in Amahara region across 
subsequent visits 2008 to 2016 
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5.4 EXPLORATORY DATA ANALYSIS 
5.4.1 Individual Profile 
Before proceeding to the formal statistical analysis we have described the data by 
exploring how individuals change in BMI over time. To make the individual profile plot 
more informative we have prepared it for the first 100 individuals (figure 3) 
 
 
Figure 5 Individual profile plot of BMI over time for the first 100  individuals at 
second line ART in Amhara region, 2008-2016 
According to this plot the BMI status of patients has high variability within an individual 
over time and variability between individuals at baseline and through time. 
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5.4.2 Individual profile by sex 
 
 
 
Figure 6 Individual profile for female and male patients on second line ART in 
Amhara region 2008-2016 
 
There is variation between individuals and within individuals in both male and females. 
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5.4.3 Exploring the mean profile  
Since first objective of the study was exploring the mean of BMI over time. We have 
used mean profile plot over time. As stated above all measurements in the data have no 
similar time of measurements therefore we have used smoothing to determine its 
evolution. 
 
 
Figure 7Time plot of BMI versus time in months with lowess smoothed curve 
superimposed for HIV patients on second line ART in Amhara region 2008-2016  
The mean profile of BMI shows a linear increase over time  
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5.4.4 Mean profile for females and males respectively 
 
Figure 8 Time plot of BMI versus time in months with lowess smoothed curve 
superimposed for HIV patients on second line ART in Amhara region separated 
by sex 2008-2016  
The plot shows a linear increment of BMI in both females (1) and males (2) over time.  
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5.5 Exploring the correlation structure and scatter plot of correlation matrix 
Since this is a repeated measurement we expect some sort of correlation between 
consecutive measurements. In this case there is a positive correlation between 
subsequent measurements ( table 3 , figure 10). 
 
Table 3 Correlation matrix of BMI over time 
 
             |     BMI0     BMI1     BMI2     BMI3     BMI4     BMI5     BMI6     BMI7     BMI8     BMI9    BMI10    BMI11 BMI12 
-------------+------------------------------------------------------------------------------------------------------------------------------------------------------ 
        BMI0 |   1.0000 
        BMI1 |   0.8668   1.0000 
        BMI2 |   0.7992   0.9248   1.0000 
        BMI3 |   0.7902   0.8676   0.8963   1.0000 
        BMI4 |   0.8416   0.9230   0.8988   0.9353   1.0000 
        BMI5 |   0.8337   0.9164   0.9253   0.9155   0.9563   1.0000 
        BMI6 |   0.4834   0.4246   0.3667   0.5032   0.4892   0.4901   1.0000 
        BMI7 |   0.8655   0.8665   0.8470   0.8757   0.8972   0.9161   0.7251   1.0000 
        BMI8 |   0.8666   0.9002   0.8961   0.9132   0.9333   0.9472   0.6097   0.9669   1.0000 
        BMI9 |   0.8978   0.8795   0.8943   0.8725   0.9296   0.9356   0.5126   0.9258   0.9505   1.0000 
       BMI10 |   0.8827   0.9198   0.9069   0.8907   0.9210   0.9282   0.5194   0.9352   0.9582   0.9568   1.0000 
       BMI11 |   0.8619   0.8885   0.8830   0.8997   0.9194   0.9154   0.5677   0.9422   0.9618   0.9568   0.9722   1.0000 
       BMI12 |   0.8359   0.8897   0.8822   0.8849   0.9138   0.9026   0.5704   0.9347   0.9508   0.9433   0.9743   0.9790 1.0000 
 
Pair wise scatter plot matrix also showed a positive and linear relationship between BMI 
at different time points 
 
 
               Figure 9 scatter plot matrix for pairs of observation times  
The scatter plot matrix also shows a positive linear relationship between BMI 
measurements taken at subsequent measurements.  
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5.6 Univariate Marginal model  
Predictor variables which show association at significance level of 0.25 were age, 
gender, CD4 count, WHO stage, functional status, educational status, occupational 
status, opportunistic infection, Tuberculosis, second line ART regimen, CPT, and INH. 
 
Table 4 Correlation structure checking and model comparison 
 Unstructured Identity Exchangeable 
AIC 14337.93 17775.34 17666.17 
BIC 14531.08 17956.02 17853.09 
 
So the model with lowest AIC was chosen, in this case the unstructured correlation 
structure. 
The need for random slop and intercept was checked by likelihood ratio test of model 
without a random intercept, with only random intercept and a model with both random 
intercept and slop.  
 
Table 5 Random Effects Models comparison  
Random effects                                                LR X2                       P value 
Model1 intercept                                           5625.28 0.0000 
Model2 intercept, time                                    297.13 0.0000 
 
So as we can see from the above tables the inclusion of random intercept and random 
slop is reasonable so in the final model we have used both random intercept and 
random slop. 
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Normality assumption 
The assumption of normality was checked by Q-Q plot. We have also compared the 
origional data with log and squre root transformed one (annex 1). Since approximately 
the origional one showed a lesser deviation from the normal line we have used the 
origional data for the final model 
 
 
Figure 10 Normal Q-Q plot for BMI 
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Figure 11 Histogram of residuals 
The histogram of residuals show approximately normal distribution 
 
5.7 Model diagnostics 
We have checked the goodness of fit by making model diagnostic plot (Figure 8) 
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Figure 12  Model diagnostic plot 
As we can see from the above plot the residuals are concentrated to the value of zero 
showing a good fit. 
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5.8 Factors affecting BMI  
Factors found to have a significant effect on the evolution of BMI over time at 
multivariable linear mixed effect model were treatment duration, age, good adherence 
INH prophylaxis, CPT, NGO employement, ambulatory, bedridden, WHO stage III, 
WHO stage IV and CD4 count. Time interaction of tertiary education, ambulatory 
functional status, and WHO stage III had significant association. 
The final model of this study is 
BMI = 18.4 + 0.04(time) + 0.04(age) + 1.9 (Nongovemp.) + 0.6 (good adherence) + 
0.7(INHgiven) + 0.8(CPTgiven) + 0.02(teritiaryedu#time) – 1.6(Ambulatory) + 
0.3(Ambulatory#time) – 1.8(Bedridden) – 0.4 (WHOstageIII) + 0.01  (WHOstageIII#time) 
– 0.8 (WHOstageIV)  + 0.001(CD4count)  
As displayed above 3 continuous and 8 categorical variables, 3 predictors time 
interaction were significantly associated with BMI. 
The intercept of BMI of patients was 18.4 kg/m2 (95% CI 16.8, 20.05). When we see the 
variability explained by covariates considered keeping all other variables at constant, 
For a one month increase in treatment duration the BMI of patients increases by 0.04 
(95% CI 0.01,  0.07). Patients who work in NGOs have a 1.9kg/m 2 (95% CI 0.24, 3.52) 
BMI increment when compared to governmental employees. But there were no 
significant difference between government employees and private, unemployed and 
others. For a unit increase in the age of a patient the BMI was increased by 0.04 (95% 
CI 0.01 0.07). When compared with patients with poor ART adherence those who had 
good adherence had increased BMI (𝛽=0.6 95% CI 0.04, 1.14). Those individuals who 
took INH had a 0.7 kg/m2 (95% CI 0.22,   1.36) increment in BMI as compared to their 
counter parts. Compared to patients who didn’t take CPT those who took had their BMI 
increased by 0.8 kg/m2 (95% CI 0.2, 1.3). Patients who attend tertiary school have 
better evolution in BMI when compared to those who lack formal education (𝛽=0.02, 
95% CI 0.003, 0.04). Individuals who were ambulatory and bedridden had decrement in 
their BMI by 1.6 kg/m2 (95% CI -1.91, -1.26) and 1.8 kg/m2 (95% CI -2.45, -1.21) 
respectively. And time interaction of ambulatory status showed a better evolution (𝛽 
=0.03 95% CI 0.013, 0.05) as compared to those with working functional status. 
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Patients on WHO stage III and WHO stage IV have decreased BMI by 0.4 (95% CI -
0.62, -0.16) and 0.8 (-1.17   -0.36) as compared to WHO stage I. And over time those at 
WHO stage III had a higher evolution (𝛽=0.01 95% CI 0.01, 0.02 ) compared to WHO 
stage I. But no significant difference was seen between WHO stage I and WHO stage II. 
CD4 count of patients had also a positive association with BMI that is for a unit increase 
in CD4 count BMI increased by 0.001 kg/m2 (95% CI 0.001, 0.001). The standard 
deviation of the intercept sd (constant) was 3.3 which shows a significant BMI difference 
between subjects at baseline and standard deviation of slop was 0.04 which shows that 
there is significant variation between individuals over time.  
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Table 6 Parameter estimates for full linear mixed effect model 
 
BMI 
 
Coefficient  
 
[  95% conf. interval] 
INTERCEPT   18.4        (16.8,  20.05)*** 
Time   0.04   ( 0.01,  0.07)* 
Sex( Female)   0  
Male  -0.16   (-0.67,   0.34) 
Female#time 0  
Male#time  0.003   (-0.01,   0.01) 
Age   0.04   ( 0.01   0 .07)** 
Poor adherence  0  
Fair adherence   0.4    ( -0.2,   1.06) 
Good adherence  0.6    (0.04    1.14)*    
Poor adherence#time 0  
Fair adherence#time 0.004    (-0.01,  0.18) 
Good adherence#time -0.002    (-0.01,  0.01) 
INH given (No)  0  
INH given (Yes)  0.7    (0.22,   1.36)** 
INH given(No)#time 0  
INH given(Yes)#time 0.004  (-0.01 ,  0.01)             
CPT given (No) 0  
CPT given (Yes) 0.8     (0.25, 1.39)**           
CPT given (No)#time 0  
CPT given (Yes) -0.015    (-0.02 , 0.03)             
TB history (No) 0  
TB history (Yes) -0.58    (-1.30, 0.14)           
TB history (No)#time 0  
TB history (Yes)#time -0.01  (-0.02 ,  0.01)                
OI (No) 0  
OI (Yes) -0.53  (-1.12 , 0 .07)                
OI(No)#time 0  
OI(Yes)#time 0.004  (-0.01 , 0 .02)               
Occupation ( Gov’t) 0  
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BMI 
 
Coefficient  
 
[  95% conf. interval] 
Unemployed  0.34   (-0.39 , 1.07)            
NGO employee 1.9    (0.24, 3.52)*              
Private 0.25   (-0.81 , 1.32)                 
Other 0.45    (-0.7 ,  0.79)              
Occupation(Gov’t)#time 0  
Unemployed#time 0.05   (-0.01 , 0.02)                 
NGO employee#time 0.02  (-0.01  , 0.54)                    
Private#time 0.0002  (-0.21 , 0.22)       
Others#time 0.005  (-0.01   , 0.02)                   
Education(Noeducation) 0  
Primary  -0.04  (-0.73   , 0 .66)  
Secondary  0.56  (-0.12   , 1.25)   
Tertiary  0.89  (-0.07   , 1.85)     
No education#time 0  
Primary#time -0.003  (-0.02   , 0.01) 
Secondary#time 0.01   (-0.01  , .002)   
Tertiary#time 0.02  (0.003 , 0.04)* 
Functional (Working) 0  
Ambulatory -1.6 (-1.91   -1.26)*** 
Bedridden  -1.8 (-2.45   -1.21)*** 
Functional (Worki)#time 0  
Ambulatory#time 0.03 (0.013    0.05)*** 
Bedridden#time -0.004 (-0.04  0 .03) 
WHO stage I 0  
WHO stage II -0.01 (-0.39    0.38) 
WHO stage III -0.4 (-0.62   -0.16)*** 
WHO stage IV -0.8 (-1.17   -0.36)*** 
WHO stage I#time 0  
WHO stage II#time 0.003 (-0.01   0.02) 
WHO stage III#time 0.013 (0.01    0.02)*** 
WHO stage IV#time -0.01 (-0.02   0 .012) 
32 
 
 
BMI 
 
Coefficient  
 
[  95% conf. interval] 
ART regimen (ABC based) 0  
TDF based regimen 0.3 (-0.27    0.85) 
AZT based regimen 0.2 (-0.52   0.89) 
Other regimens  -0.02 (-1.05   1.01) 
ABC  based regimen#time 0  
TDF based regimen#time -0.01 (-0.02   0.002) 
AZT based regimen#time 0.00001 (-0.02   0.02) 
Other regimens#time  -0.02 (-0.03,  .001) 
CD4 count 0.001 (0.0007    0.0014)*** 
 
 
Random-effects Parameters   Estimate [95% Conf. Interval] 
id: Unstructured                
sd(time)              0.04     (0.036, 0.046) 
sd(_cons)              3.3       (3.13, 3.48) 
corr(time,_cons)              0.03         (-0.09, 0.14) 
sd(Residual)              0.97         (0.94, 0.99) 
 
LR test vs. linear model: chi2(3) = 5895.95               Prob > chi2 = 0.0000 
*** P value < 0.001      ** P value < 0.01             *P value <0.05 
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6. DISCUSSION 
This study has found a linear increment in BMI of patients over time. There were BMI 
differences between subjects at baseline and in their progress over time. 
Factors related to increment in BMI were age, NGO employment, treatment duration, 
INH prophylaxis, CPT prophylaxis, CD4 count and good adherence. And factors 
associated with a negative change in BMI were ambulatory functional status, bedridden 
functional status, WHO stage III and WHO stage IV. 
 
For a one month  increase in treatment duration the BMI of patients increases by 0.04, 
this finding is in line with a study in South Africa (RRR = 1.01) (37). The possible 
reasons for weight gain could be due to normal reversion of the weight loss associated 
with HIV or due to drug related metabolic changes which include hyperlipidemia, insulin 
resistance and diabetes(38) Or due to the growing life style change of sub Saharan 
countries to European way of living which includes high energy intake, high dietary fat 
and sugar and less physical activity(39).  
 
For a one unit increase in the age of a patient BMI was increased by 0.04 kg/m2. The 
finding is in line with a study conducted in multicenter study in low resource setting 
which shows a lower probability of weight loss in older individuals when compared to 
younger age groups less than 29 years(13). A study conducted in Swiss also showed a 
similar but higher change in BMI with age (𝛽 = 0.15, 95% CI 0.06–0.24 kg/m2) (40). This 
association could be due to  increased risk of lipid accumulation in HIV patients as age 
increases(38) 
 
Patients who work in NGOs have a 1.9kg/m2 BMI increment when compared to 
governmental employees this could be due to a better payment in NGOs which helps 
them access a balanced diet and improve their health status(42).  
 
There were no difference in BMI change in patients with different educational level at 
baseline but patients who have tertiary educational level have a higher evolution from 
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those with no education (𝛽=0.02). Possible reason can be a higher educational level 
enabling them to better understand and live a health conscious life style(43).  
 
When compared with patients with poor ART adherence those who have good ART 
adherence had increased BMI by 0.6 kg/m2. This finding is in line with a study in Hanoi, 
Vietnam, 2.6 kg increase in the first 6 months of treatment in those who have very good 
adherence(31) and in a study from South Africa also higher probability of weight gain 
was seen in those who have good adherence as compared to poor adherence, RRR 
1.51.(37) The possible reason could be the strong association of good adherence to 
viral suppression and improved clinical outcome of therapy including weight gain(44).  
 
Patients who took Isoniazid prophylaxis (INH) and Cotrimoxazole prophylaxis (CPT) 
have 0.8 and 0.7 kg/m 2 BMI increase when compared to their counter parts. This finding 
has similar association with a multicenter controlled clinical trial in Africa (45). This could 
be due to the greatly increased appetite associated with the prophylactic drugs(46). INH 
also augments the effect of ART (47).  
 
Patients whose functional status was ambulatory and bedridden had a decreased BMI 
by 1.6 kg/m2 and 1.8kg/m2 respectively when compared to those who are working. This 
could be due to their inability to work they may not access nutritious and balanced diet 
which affects their BMI. Or it could be due to additional decreased immunity caused by 
physical inactivity which makes them more susceptible to minor infections leading to a 
higher calori loss (48) But those patients who were ambulatory have a higher evolution 
of BMI when compared to working (𝛽=0.03, 95% CI 0.013, 0.05).  
 
Patients on WHO stage III and WHO stage IV have decreased BMI by 0.4 and 0.8 
respectively as compared to WHO stage I. and over time those at WHO stage III have a 
higher evolution (𝛽 =0.013 95% CI 0.01, 0.02). This finding is in line with a multicenter 
study in resource limited settings which shows individuals who had high clinical status ( 
WHO stage III and WHO stage IV) had poorer weight gain when compared to weight 
change in patients at lower WHO stage -2.26 kg(13). The possible reason can be 
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unexplained chronic diarrhea and HIV enteropathy in these patients and the associated 
malabsorption(7) or it could be due to pyrexia of unknown origin in the late stage of the 
disease which results an increased calori loss and wasting(49).  
 
For a unit increase in CD4 count BMI was increased by 0.001 kg/m2 this positive 
association is supported by evidence from a study conducted in Boston which states 
that for a unit increase in CD4 cells weight increases by 0.35 kg(14). A study from  
Tanzania also shows increment in weight with increment in CD4 count(30). This 
increase can be explained by association of increment of CD4 count with a good clinical 
changes like viral supression, improved immunity and apitite leading to increment in the 
BMI of patients (13).  
 
Clinical and Public health importance of this study is health care professionals can 
monitor and follow the response of their patients on ART by easily available, 
inexpensive and good predictor of the outcome of therapy and know in which factors 
they can intervene. 
Since viral load, CD4 count and other measurements are expensive and inaccessible, 
the ministry of health can consider BMI as initial predictor of treatment outcome in 
resource limited areas. It can help the public in general to access further investigations 
by early predicting the treatment success and easily intervene per findings.  
Strength and limitation of the study  
Being a retrospective study we were unable to find some predictors like viral load, 
alcohol and smoking marital status. The main strength of this study was the method of 
analysis, the use of longitudinal data analysis which can handle both time variant and 
non time variant covariates, good for missing data and irregularly spaced observations. 
This method also considers all sources of variation, time interaction effect of variables 
and subject specific parameters.   
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7. CONCLUSION 
 
This study has found a linear increment in BMI of patients over time.  
Factors related to increment in BMI are age, treatment duration, INH prophylaxis, CPT, 
NGO employment, CD4 count and good adherence.  
Factors associated with a negative change in BMI were ambulatory functional status, 
bedridden functional status, WHO stage III and WHO stage IV. 
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8. RECOMMENDATION 
To Health care providers 
 We recommend the health professionals to provide INH and CPT prophylaxis to 
all patients giving a special attention for those who are on WHO stage III and IV. 
 Health care providers shall give all possible interventions to improve adherence 
of patients and to make them stay long on treatment. They shall also consider 
the negative impacts of being overweight /obese. 
To the government 
 We suggest to give special support for patients who are bedridden and 
ambulatory.  
To researcher  
 Other important predictors like alcohol use, smoking, viral load need further 
study. 
 The effect of increment in BMI of patients on cardiovascular disease needs 
further study. 
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10. ANNEX 
Normal Q-Q plot and mean profile by adherence level 
           
1
0
2
0
3
0
4
0
1
0
2
0
3
0
4
0
0 50 100
0 50 100
1 2
3B
M
I
time
bandwidth = .8
Lowess smoother
-2 0 2
0
.9
1
.0
1
.1
1
.2
1
.3
1
.4
1
.5
Normal Q-Q Plot(logBMI)
Theoretical Quantiles
S
a
m
p
le
 Q
u
a
n
ti
le
s
-2 0 2
3
.0
3
.5
4
.0
4
.5
5
.0
5
.5
Normal Q-Q Plot(sqrtBMI)
Theoretical Quantiles
S
a
m
p
le
 Q
u
a
n
ti
le
s
39 
 
Data collection Check list  
This checklist is prepared for the collection of socio-demographic, clinical, immunological, treatment and outcome related information that are 
important for the assessment of weight of HIV patients on second line ART in University of Gondar Hospital, FelegeHiwot referral Hospital, 
Debremarkos, Debrebirhan, Dessee referral hospital Woldya hospital,Debre Tabor Hospital and Finoteselam hospital. All this information will be 
retrieved from the clients ART registration book and from individual patient card without mentioning the name of clients. This information will be 
collected by health care providers (BSc nurse or Health Officer) possibly working in the ART clinic of the hospitals. Contact +251918068580 
Part I: Baseline variables  
S.No Variables  Categories       
101. Hospital/Facility        
102. Patient_MRN number       
103. Patient-ART number       
104. Age at enrollment       
105. Date of enrollment ----/-----/-----      
106. Gender  1 Female            2 Male     
107. Address  Zone_________ Woreda______  Kebele_______   
108. Marital status  1. Single               2. Married              3.Divorced  4. Widowed  5. Separated   
109. Education  1.No education 2.Elementary   3 .Secondary  4 .Tertiary    
110. Occupation  1.Unemployed      2.Government  3.Non gov’t 4. Private     5 .Other 
111. Pastopportunistic infections     1  Yes               2. No      112a. If yes, Specify ____   
112. Past TB treatment history 1. Yes      2. No 3. Not recorded    
113. Is the treatment completed? 1. Yes                   2. No     
114. Substance use  1 Tobacco 2. Alcohol 3. Khat 4. None   
115. Baseline  Weight  ___________kg      
116. Baseline  Height  ___________m       
117.  Base line CD4  -------      
118. Baseline WHO stage  1 Stage I       2. Stage II    3. Stage III 4. Stage IV   
119. Baseline  Functional status  1 Working         2.Ambulatory  3. Bedridden    
120. Date  the regimen changed to 
second line  
-----/-----/--------    (DD/MM/YY)    
121. Second line regimen 1. 2a 
2. 2b 
3. 2c 
4. 2d 
5. 2e 
6. 2f 
7. 2g 
8. 2h 
9. 2i 
10. Other--
- 
 
122. Viral load at switch 1. Undetectable(<400 cell/ml) 2. 400-10,000c/ml 3.>10,000c/ml 3. Not done 
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Part III: Follow-up variables after switch to second line ART 
Date 
ofsecond 
lin 
Followu
p 
 
Weigh
t 
 
Functiona
l  
Status  
 
WH
O 
stage  
 
TB 
scree
n 
(P/N) 
 
OIs 
INH CPT ARV drug   
Adherenc
e 
C
o
d
e 
o
f 
re
g
im
en
 
Regimen 
change(Y/N
) 
R. for 
chang
e 
Side 
effec
t  
Hemoglobi
n level 
CD4 
coun
t  
BM
I 
                
                
                
                
                
                
                
                
                
 
Collected by: Name ____________________________                        Signature ____________                                        Date ________________ 
Supervised by: Name ___________________________                        Signature ____________                                        Date _______________
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